Imitong

Indications

• Babesiosis in animals
• Protozoal infections in veterinary medicine

Dosage

Children: For paediatric dosing, consult the BNF for Children for appropriate recommendations.

Adults: For adults, refer to the specific dosage guidelines as per the BNF.

Mechanism of action

Imidocarb exerts its effects by inhibiting the enzyme dihydrofolate reductase, which is crucial for the synthesis of tetrahydrofolate, a form of folic acid necessary for DNA synthesis and cell division in protozoa. This disruption in folate metabolism leads to impaired nucleic acid synthesis, ultimately resulting in cell death.

Pharmacodynamics

The pharmacodynamics of imidocarb involves its action on protozoal organisms, leading to the inhibition of their growth and replication. The drug is effective against both the asexual and sexual stages of Babesia parasites, providing a therapeutic effect in treating infections. Its selectivity for protozoa over mammalian cells contributes to its therapeutic window.

Pharmacokinetics

Imidocarb is well absorbed after parenteral administration, with peak plasma concentrations occurring within a few hours. It is metabolized in the liver and has a half-life that varies depending on the route of administration and the species treated. The drug is excreted primarily via the urine, with some metabolites also eliminated in the feces. Its pharmacokinetic profile may differ amongst species, necessitating careful consideration when dosing.

Contra-indications

• Hypersensitivity to imidocarb or any of its components.
• History of seizures or epilepsy.
• Pregnancy.

Adverse effects

• Drowsiness.
• Ataxia.
• Vagal stimulation leading to bradycardia.
• Tremors.
• Gastrointestinal upset including vomiting and diarrhea.
• Hypersensitivity reactions including rash.

Interactions

• May enhance the effects of other anticholinergic drugs.
• Concurrent use with cholinesterase inhibitors may antagonize the effects of imidocarb.

Precautions

• Use with caution in patients with liver or kidney impairment.
• Monitor for signs of toxicity, especially in patients with a history of seizures.

Pregnancy

Imidocarb should not be used during pregnancy due to potential risk to the fetus.

Breast-feeding

It is not known if imidocarb is excreted in human milk, caution is advised.

Storage

Store in a cool, dry place, protected from light.

Formulations

• Injectable solution.

Indications

• Pain management
• Vaccination
• Antibiotic therapy
• Hormonal therapies
• Anesthesia
• Nutritional support
• Chemotherapy

Dosage

Children: Refer to specific drug guidelines for paediatric dosing, as it requires careful consideration of weight and age.

Adults: Refer to specific drug guidelines for adult dosing, as it varies widely depending on the medication and clinical condition.

Mechanism of action

The mechanism of action of injected drugs varies widely based on the specific medication being administered. Generally, injected drugs enter the bloodstream directly, allowing them to circulate rapidly throughout the body. For instance, antibiotics may work by inhibiting bacterial cell wall synthesis, while analgesics may modulate pain pathways in the central nervous system. Each drug has unique pathways through which it achieves its therapeutic effects.

Pharmacodynamics

Pharmacodynamics refers to the effects of drugs on the body and their mechanisms of action. For injectable medications, effects can be immediate or delayed, depending on the drug's formulation and route of administration. Factors influencing pharmacodynamics include receptor affinity, drug concentration, and the presence of other substances that may enhance or inhibit the drug's effects. For example, some injectable drugs may require specific receptors to exert their effects, while others may have a broader range of action.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of injected drugs. After administration, drugs are rapidly absorbed into the bloodstream, leading to quick therapeutic effects. The distribution depends on factors such as blood flow, tissue permeability, and protein binding. Drugs are metabolized primarily in the liver and excreted through the kidneys or bile. The pharmacokinetic profile can vary widely based on the drug's chemical nature, dosage, and individual patient factors.

Pregnancy

Safety during pregnancy depends on the specific injection and its active ingredients. It is essential to consult a healthcare professional for guidance.

Breast-feeding

The safety of injections during breastfeeding varies by the specific medication. It is recommended to seek advice from a healthcare provider.

Storage

Store injections as per manufacturer's guidelines, usually in a cool, dry place away from direct sunlight. Some may require refrigeration.

Indications

• Food preservation
• Antioxidant in pharmaceuticals
• Treatment of certain conditions related to sulfite sensitivity

Dosage

Children: Refer to BNF for Children for appropriate paediatric dosing guidelines.

Adults: Refer to specific formulations and clinical guidelines for appropriate dosing, as it varies based on the condition being treated.

Mechanism of action

Metabisulfite acts primarily as a reducing agent, which means it can donate electrons to other compounds, thereby preventing their oxidation. This property is utilized in food preservation and in various chemical reactions. The compound participates in metabolic pathways such as the thiosulfate oxidation and sulfur oxidation pathways, suggesting its role in sulfur metabolism within certain organisms.

Pharmacodynamics

Metabisulfite's pharmacodynamics involve its role as an antioxidant and a preservative. By preventing the oxidation of sensitive compounds, it helps maintain the stability and efficacy of pharmaceuticals and food products. However, it can also induce allergic reactions in sensitive individuals, particularly in those with asthma.

Pharmacokinetics

Metabisulfite is rapidly absorbed when ingested and is metabolized in the body to sulfate, which is then excreted via the kidneys. Its half-life and specific pharmacokinetic parameters can vary based on the route of administration and individual patient factors.

Indications

• Pain relief
• Anti-inflammatory treatment
• Management of osteoarthritis
• Management of rheumatoid arthritis
• Treatment of dysmenorrhea
• Postoperative pain management

Dosage

Children: Refer to specific propionic acid derivative product monographs for paediatric dosing as it varies by formulation and condition treated.

Adults: Refer to specific propionic acid derivative product monographs for adult dosing as it varies by formulation and condition treated.

Mechanism of action

Propionic acid and its derivatives exert their effects primarily through the inhibition of cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins. This results in reduced inflammation, pain, and fever. By blocking COX-1 and COX-2 pathways, propionic compounds modulate the inflammatory response and provide analgesic effects.

Pharmacodynamics

Propionic compounds have a rapid onset of action, with effects noticeable within 30 minutes to an hour after administration. The anti-inflammatory effects are dose-dependent, and the duration of action typically lasts for several hours. The analgesic properties are also evident in acute and chronic pain management, providing relief from conditions such as arthritis, menstrual pain, and musculoskeletal disorders.

Pharmacokinetics

After oral administration, propionic acid is rapidly absorbed from the gastrointestinal tract. It is primarily metabolized in the liver, undergoing glucuronidation and oxidation. The elimination half-life of propionic derivatives varies but generally ranges from 1 to 4 hours. These substances are excreted primarily through urine, with a small fraction eliminated in feces. Due to their short half-lives, multiple dosing may be required to maintain therapeutic levels.

Contra-indications

• Hypersensitivity to propionic acid or its derivatives
• Active peptic ulcer disease
• Severe renal impairment

Adverse effects

• Gastrointestinal disturbances (nausea, vomiting, diarrhea)
• Dizziness
• Headache
• Rash
• Tinnitus
• Hepatotoxicity (rare)

Interactions

• Increased risk of gastrointestinal bleeding with NSAIDs
• Inhibition of renal excretion of certain drugs (e.g., lithium)
• Potential additive effects with other central nervous system depressants

Precautions

• Use with caution in patients with renal or hepatic impairment
• Monitor for signs of gastrointestinal bleeding in long-term use
• Caution in patients with asthma, as propionic acid derivatives may exacerbate symptoms

Pregnancy

Use in pregnancy only if clearly needed. Animal studies have shown adverse effects. There is limited data on human pregnancy.

Breast-feeding

Use with caution while breastfeeding. Propionic acid and its derivatives may pass into breast milk.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Oral tablets
• Oral suspension
• Topical formulations (creams, gels)